Authors
Latest:
Dr. McCloskey on Postoperative Radiation in Patients With Breast CancerSusan A. McCloskey, MD, MSHS, assistant professor of radiation oncology, University of California Los Angeles (UCLA) Medical Center, Jonsson Comprehensive Cancer Center, discusses the evolution of postoperative radiation in patients with breast cancer.
Latest:
Dr Modesitt on Shared Decision-Making When Choosing PARP Inhibitors in Ovarian CancerSusan C. Modesitt, MD, FACOG, FACS, discusses the role of PARP inhibitors in the treatment of patients with ovarian cancer.
Latest:
Dr Domchek on the Importance of Germline Testing in Breast Cancer CareSusan Domchek, MD, FASCO, discusses the importance of germline testing in breast cancer care.
Latest:
Dr. Prockop Discusses Tabelecleucel in Post-Transplant EBV+ LymphomasSusan E. Prockop, MD, pediatric oncologist, Memorial Sloan Kettering Cancer Center, discusses tabelecleucel in patients with Epstein-Barr virus (EBV)-associated post-transplant lymphomas.
Latest:
Dr. Slovin on Considerations for Treatment Selection in Nonmetastatic CRPCSusan F. Slovin, MD, PhD, discusses considerations for treatment selection in nonmetastatic castration-resistant prostate cancer.
Latest:
Dr. Galbraith Discusses Phase I/II Results for AZD9291 in Advanced NSCLCSusan Galbraith, MD, PhD, head, Oncology Innovative Medicine, AstraZeneca, discusses updated data from the ongoing phase I/II AURA study looking at AZD9291 for NSCLC.
Latest:
Overall Survival Analysis Between African-American and Caucasian Men with mCRPCSusan Halabi, PhD, professor of biostatistics and bioinformatics, School of Medicine, Duke Cancer Institute, discusses an analysis of overall survival (OS) between African-American and Caucasian men with metastatic castration-resistant prostate cancer.
Latest:
Novel Radiotherapy Techniques Expand Options for Breast Cancer PatientsThose of us who have treated patients with breast cancer for any extended period of time can likely share anecdotes about watching the treatment of this disease evolve to levels many of us could only have imagined when we began practicing.
Latest:
Susan Lutgendorf on Impact of Minimal Support on Patients With Ovarian CancerSusan Lutgendorf, PhD, professor and Starch Faculty Fellow, Psychological and Brain Sciences, College of Liberal Arts and Sciences, University of Iowa, discusses the impact of lack of support on patients with ovarian cancer. Lutgendorf spoke on this during an interview at the SITC 31st Annual Meeting and Associated Programs.
Latest:
Dr. O'Brien Discusses Combination Venetoclax in CLLSusan M. O’Brien, MD, hematologist/oncologist at University of California, Irvine Health, discusses combination venetoclax (Venclexta) in the treatment of patients with chronic lymphocytic leukemia.
Latest:
Dr O’Brien on the Potential Role for Noncovalent BTK Inhibitors in MCL and CLLSusan M. O’Brien, MD, discusses the potential role for noncovalent BTK inhibitors in the treatment of patients with mantle cell lymphoma or chronic lymphocytic leukemia.
Latest:
Susan Moore on Oral Oncolytic Patient EducationSusan Moore on the Importance of Oral Oncolytic Patient Education
Latest:
Effective Management and Prevention of Neratinib-Induced DiarrheaSafety data from clinical trials suggest that a prophylactic regimen reduces both the severity and duration of neratinib-associated diarrhea.
Latest:
Dr. Chi on Response to Tazemetostat in Children With INI1-Negative TumorsSusan N. Chi, MD, senior physician, director, Pediatric Brain Tumor Clinical Trials Program, Dana-Farber Cancer Institute, assistant professor of pediatrics, Harvard Medical School, discusses response to tazemetostat in children with INI1-negative tumors.
Latest:
Dr. Susan O'Brien on Next-Generation Small Molecules in CLLSusan O’Brien, MD, Associate Director for Clinical Science for the Chao Family Comprehensive Cancer Center and Medical Director of the Sue and Ralph Stern Center for Cancer Clinical Trials and Research, UC Irvine Health, discusses upcoming agents in chronic lymphocytic leukemia (CLL).
Latest:
Putting Key Developments in Two Tumor Types in FocusAs the molecular understanding of breast cancer continues to evolve, the search for treatment targets based upon tumor subtypes and gene expression patterns is intensifying.
Latest:
BATTLE-2: Next-Generation of Biomarker-Driven TrialsWhile the number of known mutations and matching targeted agents is relatively limited at present, clinical trials are being designed to identify effective therapies for specific mutations more efficiently.
Latest:
Dr. Slovin on Selecting Among Available Treatment Options in mCSPCSusan F. Slovin, MD, PhD, discusses selecting among available treatment options for patients with metastatic castration-sensitive prostate cancer.
Latest:
Oncology Nutritionists: Should cancer care teams include dietary experts?Early screening and comprehensive assessment of risk for malnutrition is increasingly recognized as imperative in the development of standards of quality of care in oncology practices.
Latest:
Dr. Campos Discusses Differences Between PARP Inhibitors in Recurrent Ovarian CancerSusana Campos, MD, MPH, assistant professor of medicine, Harvard Medical School, and Dana-Farber Cancer Institute, discusses differences between PARP inhibitors in recurrent ovarian cancer.
Latest:
Dr. Campos on Next Steps With PARP Inhibitors in Ovarian CancerSusana M. Campos, MD, gynecologic oncologist, Dana-Farber Cancer Institute, assistant professor of medicine, Harvard Medical School, discusses next steps with PARP inhibitors in ovarian cancer.
Latest:
New Agents Push the Envelope in Ovarian CancerAlthough there have been numerous studies evaluating the role of different therapy schedules, cytotoxic agents, and routes of administration in ovarian cancer, the backbone of therapy remains a combination of a platinum and a taxane.
Latest:
Dr. Ulahannan on the PRODIGE 35 Trial in Pancreatic CancerSusanna Ulahannan, MD, assistant professor, Section of Hematology/Oncology, associate director, Oklahoma TSET Phase I Program, Stephenson Cancer Center, The University of Oklahoma, discusses the phase II PRODIGE 35/PANOPTIMOX trial in pancreatic cancer.
